Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer ’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis

ConclusionsOur findings suggest that AChEI therapy may negatively impact psychological health, and careful monitoring of new psychiatric symptoms is warranted. Lowering the dose may resolve some psychiatric adverse events, as may switching to galantamine in the case of insomnia.Clinical Trial RegistrationThe study was pre-registered on PROSPERO (CRD42021258376).
Source: Drugs and Aging - Category: Geriatrics Source Type: research